GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Endoscopy/ESD for upper esophageal cancer

ESD for upper esophageal cancer

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated January 1, 2026

Quick Answer

Endoscopic submucosal dissection (ESD) is increasingly recognized as an effective and minimally invasive treatment option for superficial esophageal squamous neoplasms (ESN), including early-stage esophageal cancer. This technique is particularly suitable for treating superficial lesions confined to the mucosal or submucosal layers of the esophagus, as it allows for precise removal of the tumor while preserving the surrounding esophageal tissue.


Endoscopic submucosal dissection (ESD) is increasingly recognized as an effective and minimally invasive treatment option for superficial esophageal squamous neoplasms (ESN), including early-stage esophageal cancer. This technique is particularly suitable for treating superficial lesions confined to the mucosal or submucosal layers of the esophagus, as it allows for precise removal of the tumor while preserving the surrounding esophageal tissue.

The procedure involves the use of specialized endoscopic tools to dissect and remove the cancerous lesion en bloc (in one piece), which ensures complete removal and allows for accurate pathological assessment. ESD is recommended as the standard of care for early esophageal squamous cell carcinoma (ESCC) when the lesion meets specific criteria for curative resection, such as limited depth of invasion, absence of lymphovascular invasion, and no evidence of lymph node metastasis.

Key benefits of ESD for upper esophageal cancer include high rates of complete tumor removal (en bloc and R0 resection), low recurrence rates in curative resections, and the ability to preserve the esophagus, thereby avoiding more invasive surgical procedures like esophagectomy. However, patient selection is critical to ensure optimal outcomes, as deeper or more advanced lesions may require additional treatments such as surgery or chemoradiotherapy.

The safety profile of ESD is generally favorable, with a low risk of complications such as bleeding or perforation, though these risks increase with larger or more complex lesions. In the Western world, data on ESD for esophageal cancer is still emerging, but studies indicate that it is a viable and effective treatment option, with outcomes comparable to those reported in Asian countries where the procedure is more established.

In summary, ESD represents a safe and effective approach for the treatment of upper esophageal cancer, particularly for superficial lesions. It offers the advantages of organ preservation, accurate pathological assessment, and low recurrence rates, making it a preferred option for carefully selected patients with early-stage esophageal cancer. However, long-term follow-up and multidisciplinary care are essential to monitor for recurrence or progression, especially in cases where curative resection criteria are not met.

Related Q&A

Duodenal Mucosal Resurfacing REMAIN-1 Study: DDW | 2026

Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...

EUS-FNAB for Solid Pancreatic Lesions: GIE | July 2026

Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...

Durable Endoscopic Partial Reversal of Roux-en-Y Gastric Bypass Using Parallel LAMS Septotomy: GIE | July 2026

Introduction: Although Roux-en-Y gastric bypass (RYGB) is an effective bariatric procedure, a small proportion of patients develop severe nutritional complications, refractory dumping syndrome, or other debilitating adverse events requiring reversal. This study describes a novel...

EUS Double Drainage for Malignant Dual Obstruction : Gut | Jul 2026

Introduction: Simultaneous malignant distal biliary obstruction (MDBO) and gastric outlet obstruction (GOO), commonly caused by advanced pancreatic, biliary, or duodenal cancers, presents a major palliative challenge. Conventional endoscopic approaches often require repeated interventions and may...

Endoscopic Mucosal and Submucosal Cutting in benign esophageal stricture: Gut | July 2026

Introduction: Long benign esophageal strictures remain one of the most difficult benign conditions to manage. Although endoscopic dilation and incision techniques provide temporary relief, recurrence is common, often requiring repeated interventions. This study introduces a...

Economic Impact of POEM and ESD: GIE | June 2026

Introduction: Peroral endoscopic myotomy (POEM) and endoscopic submucosal dissection (ESD) have revolutionized the management of esophageal motility disorders and early gastrointestinal neoplasia. Despite their proven clinical benefits, widespread adoption has been limited by concerns regarding...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer